Avenue therapeutics announces exercise and closing of underwriter's over-allotment option

New york, nov. 17, 2021 (globe newswire) -- avenue therapeutics, inc. (the “company”) (nasdaq: atxi), a company focused on the development of intravenous (“iv”) tramadol for the u.s. market, today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, its option to purchase an additional 292,018 shares of common stock at a price of $1.34 per share. total gross proceeds to the company from the offering, including the funds received from the prior closing and exercise of this option, are approximately $3 million, before deducting underwriting discounts, commissions, and other offering expenses payable by the company.
ATXI Ratings Summary
ATXI Quant Ranking